- Home
- KRRO
KRRO
Korro Bio Inc.
as 07-26-2024 4:00pm EST
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 385.9M | IPO Year: | 2019 |
| Target Price: | $122.50 | AVG Volume (30 days): | 107.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -27.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.15 - $97.91 | Next Earning Date: | 08-27-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Korro Bio Inc. (KRRO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SANDELL SCOTT D | KRRO | 10% Owner | Apr 22 '24 | Buy | $56.00 | 17,857 | $999,992.00 | 1,090,793 | SEC Form 4 |
| Florence Anthony A. Jr. | KRRO | 10% Owner | Apr 22 '24 | Buy | $56.00 | 17,857 | $999,992.00 | 1,090,793 | SEC Form 4 |
| Yang Rick | KRRO | 10% Owner | Apr 22 '24 | Buy | $56.00 | 17,857 | $999,992.00 | 1,090,793 | SEC Form 4 |
| Makhzoumi Mohamad | KRRO | 10% Owner | Apr 22 '24 | Buy | $56.00 | 17,857 | $999,992.00 | 1,090,793 | SEC Form 4 |
| New Enterprise Associates 17, L.P. | KRRO | 10% Owner | Apr 22 '24 | Buy | $56.00 | 17,857 | $999,992.00 | 1,090,793 | SEC Form 4 |
| BASKETT FOREST | KRRO | 10% Owner | Apr 22 '24 | Buy | $56.00 | 17,857 | $999,992.00 | 1,090,793 | SEC Form 4 |
| Chang Carmen | KRRO | 10% Owner | Apr 22 '24 | Buy | $56.00 | 17,857 | $999,992.00 | 1,090,793 | SEC Form 4 |
| Mathers Edward T | KRRO | 10% Owner | Apr 22 '24 | Buy | $56.00 | 17,857 | $999,992.00 | 1,090,793 | SEC Form 4 |
| Atlas Venture Opportunity Fund II, L.P. | KRRO | 10% Owner | Apr 22 '24 | Buy | $56.00 | 17,857 | $999,992.00 | 195,074 | SEC Form 4 |
| Walker Paul Edward | KRRO | 10% Owner | Apr 22 '24 | Buy | $56.00 | 17,857 | $999,992.00 | 1,090,793 | SEC Form 4 |
| Lucchino David L. | KRRO | Director | Nov 22 '23 | Sell | $35.99 | 110 | $3,958.60 | 23,196 | SEC Form 4 |
| Lucchino David L. | KRRO | Director | Nov 22 '23 | Sell | $36.74 | 230 | $8,449.99 | 22,966 | SEC Form 4 |
| Lucchino David L. | KRRO | Director | Nov 22 '23 | Sell | $37.98 | 614 | $23,322.42 | 22,352 | SEC Form 4 |
| Lucchino David L. | KRRO | Director | Nov 22 '23 | Sell | $38.82 | 202 | $7,841.54 | 22,150 | SEC Form 4 |
| Lucchino David L. | KRRO | Director | Nov 3 '23 | Sell | $45.53 | 67 | $3,050.38 | 23,340 | SEC Form 4 |
| Lucchino David L. | KRRO | Director | Nov 3 '23 | Sell | $46.23 | 34 | $1,571.65 | 23,306 | SEC Form 4 |
| Lucchino David L. | KRRO | Director | Nov 3 '23 | Sell | $37.92 | 37 | $1,403.20 | 24,237 | SEC Form 4 |
| Lucchino David L. | KRRO | Director | Nov 3 '23 | Sell | $39.59 | 373 | $14,766.66 | 23,864 | SEC Form 4 |
| Lucchino David L. | KRRO | Director | Nov 3 '23 | Sell | $41.94 | 41 | $1,719.65 | 23,823 | SEC Form 4 |
| Lucchino David L. | KRRO | Director | Nov 3 '23 | Sell | $43.17 | 225 | $9,713.70 | 23,598 | SEC Form 4 |
| Lucchino David L. | KRRO | Director | Nov 3 '23 | Sell | $44.01 | 191 | $8,406.56 | 23,407 | SEC Form 4 |
Latest Korro Bio Inc. News
KRRO Breaking Stock News: Dive into KRRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Korro Joins the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
CNW Group
2 months ago
HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Business Wire
2 months ago
Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
AFP
2 months ago
New Zealand scraps plan to tax livestock burps, farts
The Wall Street Journal
2 months ago
ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility
Business Wire
2 months ago
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA
Compare KRRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KRRO Korro Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.